Difference between revisions of "Cancer drugs"

Jump to navigation Jump to search
84 bytes added ,  15:51, 18 March 2018
 
(4 intermediate revisions by the same user not shown)
Line 18: Line 18:
| Herceptin
| Herceptin
| 3345 Euros/month<ref name=spiegel8_8_11_124/>
| 3345 Euros/month<ref name=spiegel8_8_11_124/>
| breast cancer, stomach cancer
| [[breast cancer]], stomach cancer
| notes?
| notes?
|-
|-
| non-proprietary name
| gefitinib
| Iressa
| Iressa
| 3496 Euros/month<ref name=spiegel8_8_11_124/>
| 3496 Euros/month<ref name=spiegel8_8_11_124/>
| [[Lung cancer]]
| [[lung cancer]]
| notes?
| [[EGFR inhibitor]] - like erlotinib
|-
|-
| panitumumab
| panitumumab
| Vectibix
| Vectibix
| 3537 Euros/month<ref name=spiegel8_8_11_124/>
| 3537 Euros/month<ref name=spiegel8_8_11_124/>
| indication
| indication ???
| notes?
| notes?
|-
|-
Line 42: Line 42:
| Femara
| Femara
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| indication
| indication ???
| non-steroidal aromatase inhibitor
| non-steroidal aromatase inhibitor
|-
|-
Line 48: Line 48:
| Gleevec/Glivec
| Gleevec/Glivec
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| 4189 Euros/month<ref name=spiegel8_8_11_124/>
| ALL, CML
| ALL, [[CML]]
| tyrosine kinase inhibitor
| [[tyrosine kinase inhibitor]]
|-
|-
| non-proprietary name
| dasatinib
| Sprycel
| Sprycel
| 7513 Euros/month<ref name=spiegel8_8_11_124/>
| 7513 Euros/month<ref name=spiegel8_8_11_124/>
| ALL, CML
| ALL, CML
| notes?
| [[tyrosine kinase inhibitor]]
|-
|-
| nilotinib
| nilotinib
| Tasigna
| Tasigna
| 5685 Euros/month<ref name=spiegel8_8_11_124/>
| 5685 Euros/month<ref name=spiegel8_8_11_124/>
| CML
| [[CML]]
| tyrosine kinase inhibitor
| [[tyrosine kinase inhibitor]]
|-
|-
| lapatinib
| lapatinib
Line 72: Line 72:
==See also==
==See also==
*[[Cancer]].
*[[Cancer]].
*[[Neoadjuvant therapy]].


==References==
==References==
48,454

edits

Navigation menu